Back

OEP
  • English
    • English
    • 繁體中文
  • Region
    • Philippines
    • Singapore
    • Malaysia
    • Vietnam
MENU
  • Discover
  • OEP Group
    • OEP Group
    • About OEP
    • Milestone
    • Mission & Vision
    • Organization
  • Product Portfolio
    • Products
    • Product Overview
    • Prescription Medicines
    • Innovative Medical
    • Nutrition & Baby Care
    • Healthcare Supplements
    • Dermo-cosmetics
  • Business Development
    • Business Development
    • Business Development
    • Research & Development
    • Partner
  • Overseas Business
  • OEP Subsidiaries
  • Press Center
  • Investors
    • Investors
    • Investors News
    • Financial Information
    • Stock Information
    • Corporate Governance
    • Stakeholder
    • Bank Information
  • CSR
    • CSR
    • CSR Philosophy
    • Charity
    • Environmental Protection
    • Healthy Workplace
  • Careers
    • Careers
    • Talent Development
    • Total Rewards
    • Job Opportunity
  • Link
  • English
    • English
    • 繁體中文
  • Region
    • Philippines
    • Singapore
    • Malaysia
    • Vietnam
Anti-Cancer Drugs Anti-Cancer Drugs

Anti-Cancer Drugs

  • Home
  • Product Portfolio
Oral Navelbine Soft Capsule
Oral Navelbine Soft Capsule

Oral Navelbine Soft Capsule

It is a chemotherapeutic drug for non-small cell lung cancer and metastatic breast carcinoma

Package Insert
Navelbine Injection
Navelbine Injection

Navelbine Injection

It is a chemotherapeutic drug for non-small cell lung cancer and metastatic breast carcinoma

Package Insert
Pamorelin Powder
Pamorelin Powder

Pamorelin Powder

Pamorelin 3.75 mg is indicated for the palliative treatment of advanced prostate cancer.
Pamorelin 3.75 mg is indicated for the treatment of endometriosis.
Pamorelin 3.75 mg is indicated for the adjuvant therapy of female infertility in in vitro fertilization and embryo transfer (IVF-ET).

Pamorelin 11.25 mg is indicated for the palliative treatment of advanced prostate cancer.
Pamorelin 11.25 mg is indicated as concomitant to and following radiotherapy in patients with high-risk localized or locally advanced prostate cancer.

Pamorelin 22.5 mg is indicated for the palliative treatment of advanced prostate cancer.
Pamorelin 22.5 mg is indicated as concomitant to and following radiotherapy in patients with high-risk localized or locally advanced prostate cancer.
Pamorelin 22.5 mg is indicated for the treatment of central precocious puberty (CPP) in children of 2 years of age and older with an onset of CPP before 8 years in girls and 9 years in boys.

Package Insert
Kytron Inravenous Injection
Kytron Inravenous Injection

Kytron Inravenous Injection

For prevention and treatment of postoperative symptoms such as nausea and vomit after radiotherapy

Package Insert
Orimustine
Orimustine

Orimustine

Chronic lymphocytic leukemia, CLL

Package Insert

Our Products

Cardiovascular

MORE

Metabolism

MORE

Neurology

MORE

Obstetrics & Gynecology

MORE

Respiratory

MORE

Immunology

MORE

OEP

: +886-2-27554881

: oep@oepgroup.com

7F., No. 368, Sec. 1 Fu Hsing S. Rd.,
Taipei 106, Taiwan, R.O.C.

  • OEP Group
  • Product Portfolio
  • Business Development
  • Overseas Business
  • OEP Subsidiaries
  • Press Center
  • Investors
  • CSR
  • Careers
  • Link
Terms of Use | Privacy Policy

Copyright ©2021. Orient EuroPharma Co., Ltd. All rights reserved.